Ludwig from Poland

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Jounce Therapeutics, Inc. (JNCE) shares information

Jounce Therapeutics, Inc.

24h Change

4.31 %


Live rate: Market closed

Stock data per Friday 25 Sep, 2020

0.34 (+ 4.31%)
US Market is closed

Live Stock price in graph for Jounce Therapeutics, Inc. (JNCE)

  • Latest Volume

    416,508 (-54.11 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high


  • Today low


  • 52 week high


  • 52 week low


  • YTD Change


Quick links

Broker recommendations for Jounce Therapeutics

The Jounce Therapeutics, Inc. stock is rated at 1.642857 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 17 September, 2020 by a total of 7 brokers. This means that the consensus of the 7 different brokers is leaning toward to moderate buy/hold.

1 (14.29%)
0 (0%)
2 (28.57%)
1 (14.29%)
3 (42.86%)

Price target by analysts

The 5 latest analyst estimates, per Thursday 17 September, 2020, show the following high, low and average price targets.
Target Average: 14.3 USD
Target High: 28 USD
Target Low: 5.5 USD


Latest news about Jounce Therapeutics, Inc.

Below you can find the most recent news posts about Jounce Therapeutics, Inc., primarily from US and UK based news sources.

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Wednesday, 16 September 2020, 14:00:28
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
— Benzinga

Jounce inks license deal with Gilead valued up to $805M (NASDAQ:JNCE)

Tuesday, 1 September 2020, 14:47:35
Jounce Therapeutics (NASDAQ:JNCE) enters into an agreement with Gilead Sciences (NASDAQ:GILD) under which the latter will have exclusive global rights to p
— Seeking Alpha

Jounce Therapeutics Reports Second Quarter 2020 Financial Results

Friday, 7 August 2020, 08:30:00
– Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 – – On track to initiate Phase 2 SELECT …
— Benzinga

Jounce Therapeutics Reports First Quarter 2020 Financial Results

Wednesday, 6 May 2020, 12:30:00
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented…
— GlobeNewswire

What’s in Store for Jounce (JNCE) This Earnings Season?

Thursday, 20 February 2020, 16:31:00
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
— Zacks Investment Research